Companies: 48,686 Total Market Cap: 127080654394248.57

Invex Therapeutics Ltd

ASX-IXC

Healthcare Biotechnology

Rank #42969

Market Cap 4.35 M

Volume 202,419.08

Price 0.06

Change (%) 12.50%

Country or region

Australia

Invex Therapeutics Ltd's latest marketcap:

4.35 M

As of May 7, 2025, Invex Therapeutics Ltd's market capitalization has reached $4.35 M. According to our data, Invex Therapeutics Ltd is the 42969th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap	4.35 M
Revenue (ttm)	779,577.59
Net Income (ttm)	73,539.41
Shares Out	75.15 M
EPS (ttm)	0
Forward PE	0.00
Ex-Dividend Date	n/a
Earnings Date	May 7, 2025

Market Cap Chart

Data Updated: May 7, 2025

Invex Therapeutics Ltd's yearly market capitalization.

Invex Therapeutics Ltd has seen its market value drop from A$53.74 M to A$6.76 M since 2020, representing a total decrease of 87.41% and an annual compound decline rate (CAGR) of 37.90%.

Date	Market Cap	Change (%)
May 7, 2025	A$6.76 M	21.21%
December 23, 2024	A$4.96 M	-18.52%
December 27, 2023	A$6.09 M	-85.14%
December 28, 2022	A$40.96 M	-22.7%
December 31, 2021	A$52.98 M	-1.4%
December 31, 2020	A$53.74 M

Company Profile

About Invex Therapeutics Ltd

Invex Therapeutics Ltd is an Australian biopharmaceutical company focused on pioneering treatments for neurological conditions. Founded in 2019 and headquartered in Perth, the company is dedicated to advancing innovative therapies to address unmet medical needs.

Key Focus Areas

Exenatide Development: A leading treatment for neurological disorders linked to elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury.
Clinical Progress: Successfully completed Phase III clinical trials for Exenatide, demonstrating its potential as a breakthrough therapy.

Invex Therapeutics combines cutting-edge research with a patient-centric approach to deliver transformative solutions in neurology.

Frequently Asked Questions

As of May 7, 2025, Invex Therapeutics Ltd (including the parent company, if applicable) has an estimated market capitalization of $4.35 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Invex Therapeutics Ltd global market capitalization ranking is approximately 42969 as of May 7, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region	Australia
Founded	2019
IPO Date	n/a
Employees	n/a
CEO
Sector	Healthcare
Industry	Biotechnology
Address	38 Rowland Street Perth, 6008 Australia